4//SEC Filing
Mahmood Tahir Ph.D. 4
Accession 0001209191-23-059935
CIK 0001801777other
Filed
Dec 27, 7:00 PM ET
Accepted
Dec 28, 5:32 PM ET
Size
16.6 KB
Accession
0001209191-23-059935
Insider Transaction Report
Form 4
Mahmood Tahir Ph.D.
DirectorChief Executive Officer
Transactions
- Disposition to Issuer
Common Stock
2023-12-27−3,208,307→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−350,000→ 0 totalExercise: $8.29Exp: 2032-02-15→ Common Stock (350,000 underlying) - Disposition to Issuer
Common Stock
2023-12-27−484,738→ 0 total - Disposition to Issuer
Common Stock
2023-12-27−391,693→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−20,000→ 0 totalExercise: $0.34Exp: 2033-06-14→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-12-27−164,000→ 0 totalExercise: $56.61Exp: 2031-03-01→ Common Stock (164,000 underlying)
Footnotes (8)
- [F1]Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, each share of Issuer's Common Stock was converted into 0.1331 of a share of Cyclo Common Stock (the "Transaction Consideration").
- [F2]Upon closing of the Merger, the Reporting Person received Transaction Consideration of 64,519 shares of Cyclo common stock.
- [F3]Upon closing of the Merger, the Reporting Person received Transaction Consideration of 427,026 shares of Cyclo common stock.
- [F4]These shares are held directly by the Mahmood-Shamsi Living Trust Agreement for which the Reporting Person and spouse serve as co-trustees and over which shares the Reporting Person and his spouse hold voting and dispositive power.
- [F5]Upon closing of the Merger, the Reporting Person received Transaction Consideration of 52,135 shares of Cyclo common stock.
- [F6]These shares are held directly by The Mahmood 2017 Irrevocable Trust for which the Reporting Person serves as trustee and over which shares the Reporting Person hold voting and dispositive power.
- [F7]Pursuant to the Merger Agreement, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
- [F8]Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.
Documents
Issuer
Applied Molecular Transport Inc.
CIK 0001801777
Entity typeother
Related Parties
1- filerCIK 0001813286
Filing Metadata
- Form type
- 4
- Filed
- Dec 27, 7:00 PM ET
- Accepted
- Dec 28, 5:32 PM ET
- Size
- 16.6 KB